nach oben

Erschienen in:

01.03.2014 | Main topic

MicroRNA-based therapy in cardiology

verfasst von: J. Fiedler, S. Batkai, T. Thum, MD, PhD

Erschienen in: Herz | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

The pathogenic role of noncoding microRNA (miR, miRNA) has been demonstrated for several disease conditions in the heart. The underlying molecular mechanisms have been deciphered for numerous miRs that are deregulated as a result of cardiac stress. Innovative therapeutic strategies based on antifibrotic, antihypertrophic, or proangiogenic effects of miRNAs are being currently developed to improve the function of the failing heart. Identifying a safe and efficient miR-based strategy remains challenging, yet these novel approaches offer enormous potential for the treatments for heart failure. In this review we highlight the latest development in the cardiac miRNA field.

Hill JA, Olson EN (2008) Cardiac plasticity. N Engl J Med 358:1370–1380PubMedCrossRef

Cohn JN, Ferrari R, Sharpe N (2000) Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 35:569–582PubMedCrossRef

Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75:843–854PubMedCrossRef

Wightman B, Ha I, Ruvkun G (1993) Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75:855–862PubMedCrossRef

Lewis BP, Shih IH, Jones-Rhoades MW et al (2003) Prediction of mammalian microRNA targets. Cell 115:787–798PubMedCrossRef

Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120:15–20PubMedCrossRef

Rooij E van, Sutherland LB, Liu N et al (2006) A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A 103:18255–18260PubMedCentralPubMedCrossRef

Izumo S, Nadal-Ginard B, Mahdavi V (1988) Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. Proc Natl Acad Sci U S A 85:339–343PubMedCentralPubMedCrossRef

Thum T, Galuppo P, Wolf C et al (2007) MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 116:258–267PubMedCrossRef

10.

Khan R, Sheppard R (2006) Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 118:10–24PubMedCentralPubMedCrossRef

11.

Thum T, Gross C, Fiedler J et al (2008) MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456:980–984PubMedCrossRef

12.

Rooij E van, Sutherland LB, Thatcher JE et al (2008) Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 105:13027–13032PubMedCentralPubMedCrossRef

13.

Duisters RF, Tijsen AJ, Schroen B et al (2009) miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 104:170–178 (6p following 178)PubMedCrossRef

14.

Abonnenc M, Nabeebaccus AA, Mayr U et al (2013) Extracellular Matrix Secretion by Cardiac Fibroblasts: Role of MicroRNA-29b and MicroRNA-30c. Circ Res 113:1138–1147PubMedCrossRef

15.

Zhao Y, Ransom JF, Li A et al (2007) Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 129:303–317PubMedCrossRef

16.

Costa Martins PA da, Bourajjaj M, Gladka M et al (2008) Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation 118:1567–1576CrossRef

17.

Rao PK, Toyama Y, Chiang HR et al (2009) Loss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failure. Circ Res 105:585–594PubMedCentralPubMedCrossRef

18.

Zampetaki A, Willeit P, Tilling L et al (2012) Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol 60:290–299PubMedCrossRef

19.

Widera C, Gupta SK, Lorenzen JM et al (2011) Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol 51:872–875PubMedCrossRef

20.

Krutzfeldt J, Rajewsky N, Braich R et al (2005) Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438:685–689PubMedCrossRef

21.

Lennox KA, Behlke MA (2011) Chemical modification and design of anti-miRNA oligonucleotides. Gene Ther 18:1111–1120PubMedCrossRef

22.

Rooij E van (2011) The art of microRNA research. Circ Res 108:219–234PubMedCrossRef

23.

Thum T (2012) MicroRNA therapeutics in cardiovascular medicine. EMBO Mol Med 4:3–14PubMedCentralPubMedCrossRef

24.

Liu G, Friggeri A, Yang Y et al (2010) miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 207:1589–1597PubMedCentralPubMedCrossRef

25.

Chau BN, Xin C, Hartner J et al (2012) MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci Transl Med 4:121ra18PubMedCentralPubMedCrossRef

26.

Pan Z, Sun X, Shan H et al (2012) MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-beta1 pathway. Circulation 126:840–850PubMedCrossRef

27.

Ucar A, Gupta SK, Fiedler J et al (2012) The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun 3:1078PubMedCentralPubMedCrossRef

28.

Costa Martins PA da, Salic K, Gladka MM et al (2010) MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat Cell Biol 12:1220–1227CrossRef

29.

Dirkx E, Gladka MM, Philippen LE et al (2013) Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure. Nat Cell Biol 15:1282–1293PubMedCrossRef

30.

Bernardo BC, Gao XM, Winbanks CE et al (2012) Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc Natl Acad Sci U S A 109:17615–17620PubMedCentralPubMedCrossRef

31.

Boon RA, Iekushi K, Lechner S et al (2013) MicroRNA-34a regulates cardiac ageing and function. Nature 495:107–110PubMedCrossRef

32.

Fish JE, Santoro MM, Morton SU et al (2008) miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 15:272–284PubMedCentralPubMedCrossRef

33.

Solingen C van, Seghers L, Bijkerk R et al (2009) Antagomir-mediated silencing of endothelial cell specific microRNA-126 impairs ischemia-induced angiogenesis. J Cell Mol Med 13:1577–1585PubMedCrossRef

34.

Bonauer A, Carmona G, Iwasaki M (2009) MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 324:1710–1713PubMedCrossRef

35.

Fiedler J, Jazbutyte V, Kirchmaier BC et al (2011) MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 124:720–730PubMedCrossRef

36.

Meloni M, Marchetti M, Garner K et al (2013) Local inhibition of microRNA-24 improves reparative angiogenesis and left ventricle remodeling and function in mice with myocardial infarction. Mol Ther 21:1390–1402PubMedCentralPubMedCrossRef

37.

Zhou Q, Anderson C, Zhang H et al (2013) Repression of choroidal neovascularization through actin cytoskeleton pathways by MicroRNA-24. Mol Ther doi:10.1038/mt.2013.243

38.

Roncarati R, Anselmi CV, Losi MA et al (2013) Circulating miR-29a, Among other upregulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol doi:10.1016/j.jacc.2013.09.041

39.

Devaux Y, Vausort M, McCann GP et al (2013) A panel of 4 microRNAs facilitates the prediction of left ventricular contractility after acute myocardial infarction. PLoS One 8:e70644PubMedCentralPubMedCrossRef

40.

Halkein J, Tabruyn SP, Ricke-Hoch M et al (2013) MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest 123:2143–2154PubMedCentralPubMedCrossRef

41.

Jaguszewski M, Osipova J, Ghadri JR et al (2013) A signature of circulating microRNAs differentiates takotsubo cardiomyopathy from acute myocardial infarction. Eur Heart J doi:10.1093/eurheartj/eht392

Titel: MicroRNA-based therapy in cardiology
verfasst von: J. Fiedler
S. Batkai
T. Thum, MD, PhD
Publikationsdatum: 01.03.2014
Verlag: Urban & Vogel
Erschienen in: Herz / Ausgabe 2/2014
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-013-4047-0

Neu im Fachgebiet Kardiologie

Beutel versus Maschine: Beste Beatmungstechnik bei Herzstillstand gesucht

02.05.2024 Kardiopulmonale Reanimation Nachrichten

Stehen die Chancen auf eine Rückkehr der Spontanzirkulation nach Herz-Kreislauf-Stillstand bei manueller oder maschineller Beatmung besser? Und unterscheidet sich das neurologische Outcome nach der Reanimation? Das belgische Herzstillstand-Register liefert die Daten für einen direkten Vergleich zwischen Beutel und Beatmungsgerät.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

MicroRNA-based therapy in cardiology

Abstract

Neu im Fachgebiet Kardiologie

Beutel versus Maschine: Beste Beatmungstechnik bei Herzstillstand gesucht

Strenge Blutdruckeinstellung lohnt auch im Alter noch

Die „Zehn Gebote“ des Endokarditis-Managements

Sind Frauen die fähigeren Ärzte?

Update Kardiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2014

Genetische Analysen als Basis einer individualisierten Medizin bei koronarer Herzkrankheit

Cardiogenic shock due to a large VSD after myocardial infarction

Syncope as the primary manifestation of hydatid cyst

Haplotype analysis of PPARγ C681G and intron CT variants

Coexistence of cardiomyopathy and pericardial effusion

Aktuelle Kardiologie

Neu im Fachgebiet Kardiologie

Beutel versus Maschine: Beste Beatmungstechnik bei Herzstillstand gesucht

Strenge Blutdruckeinstellung lohnt auch im Alter noch

Die „Zehn Gebote“ des Endokarditis-Managements

Sind Frauen die fähigeren Ärzte?

Update Kardiologie